Visceral larva migrans (VL) is a condition caused by the migration of larvae of certain helminths, especially those of the genus Larva migrans, through human tissues. The disease is most often caused by larvae of Ascaris lumbricoides and Ancylostoma braziliense, which penetrate the skin and then migrate through the blood vessels, affecting various organs, including the liver, lungs and other systems. Clinical manifestations can vary from minor symptoms to serious pathologies associated with inflammation and damage to target organs. An important aspect of this disease is its high incidence in tropical and subtropical countries, where there are ideal conditions for the reproduction of parasites. Due to globalization and increasing population migration, cases of visceral larva migrans are becoming more frequent and require the attention of the medical community for timely diagnosis and treatment.
History of the disease and interesting historical facts
The history of visceral larval migratory disease spans decades of research and observation. The phenomenon was first described in the early 20th century, when physicians noted unusual migration patterns of larvae in patients returning from tropical regions. One of the landmark cases was the work of an American physician who, in the 1950s, studied the clinical manifestations of children who fell ill after playing on contaminated playgrounds. Since then, numerous studies have been conducted that have confirmed the pathogenetic link between larval migration and the occurrence of diffuse inflammatory processes in target organs. Interestingly, there are many myths and legends associated with “traveling worms” in various cultures, which emphasizes the awareness of the problem long before its scientific explanation.
Epidemiology
According to the World Health Organization (WHO), the annual number of cases of visceral larvae migrans in the world is tens of thousands, but most cases remain undiagnosed. The highest incidence is observed in tropical and subtropical regions, where conditions are conducive to the preservation and reproduction of larvae. According to studies, in Latin America and Southeast Asia, the prevalence rate reaches 15%. If we consider the dynamics in developed countries, the number of cases here is also increasing, which is primarily due to migration processes and the growing number of trips to tropical countries. According to statistics, the number of registered cases in the United States has doubled over the past decade, indicating the need to raise awareness among health workers.
Genetic predisposition to this disease
Current research suggests that genetics plays a role in susceptibility to visceral larval migrans. Several studies have identified mutations in genes involved in the immune response, which may modulate the body’s response to the presence of larvae. Thus, patients with certain genetic variants, such as polymorphisms in genes encoding cytokines and immune receptors, may have a higher risk of developing the disease. Examples of genes involved include IL-10 and TGF-β, which help regulate inflammation. However, while genetic predisposition plays a role, the environment and level of sanitation remain critical risk factors.
Risk factors for the development of this disease
Risk factors that contribute to the emergence of visceral larval migratory disease are varied and include both physical and chemical aspects. Key factors include:
- Contact with contaminated soil or sand, especially in warm climates.
- Lack of sanitation skills and education on how to avoid contact with larvae.
- The presence of domestic animals infected with helminths, which may be a source of larvae.
- Poor hygiene and lack of regular deworming.
- Migration of population from endemic regions to more developed countries.
Many of these factors can be mitigated through education, improved sanitation, and preventive measures. Thus, disease prevention requires a comprehensive public health approach.
Diagnosis of this disease
Diagnosis of visceral migrant larvae is based on a combination of clinical manifestations, laboratory tests and instrumental methods. The main symptoms of the disease may include:
- Fever and chills.
- Abdominal pain associated with organ damage.
- Cough, shortness of breath and other respiratory symptoms in case of lung damage.
- Allergic reactions such as rash and itching.
Laboratory tests often include blood tests for eosinophilia and specific antibodies to larvae, and radiological examinations (e.g., ultrasound, CT) can detect affected organs and identify migrating larvae. It is also important to conduct a differential diagnosis with other parasitic diseases and inflammatory processes, which requires a comprehensive approach to assessing the patient's condition.
Treatment
Treatment of visceral larvae migrans includes both general measures and specific therapy. General measures are aimed at improving the patient's general condition, including:
- Supportive therapy to relieve symptoms.
- Correction of electrolyte balance if necessary.
Pharmacological treatment usually includes anthelmintic drugs such as albendazole or mebendazole, which are active against the larvae. In some cases, when complications arise, such as abscesses or severe inflammation, surgical intervention may be required. Other treatments, such as immunotherapy, are also becoming relevant, especially in the presence of allergic reactions.
List of medications used to treat this disease
The main drugs used to treat visceral larval migratory disease are:
- Albendazole
- Mebendazole
- Ivermectin
These drugs act by interfering with the metabolic processes of helminths and causing their death. It is important that the choice of drug is at the discretion of the doctor, based on the clinical picture and individual indicators of the patient.
Disease monitoring
Monitoring the patient's condition after treatment for visceral larvae migrans involves regular check-ups, which may include:
- Repeat laboratory tests to monitor eosinophil and antibody levels.
- Clinical examinations to assess the general condition and identify possible complications.
The prognosis with adequate treatment is usually good, although complications may require a more complex approach. It is also important to consider that some patients may experience relapses of the disease, indicating the need for strict monitoring and adherence to preventive measures.
Age-related features of the disease
Visceral larva migrans may present differently in patients of different age groups. In children, the disease often has an acute onset and may be accompanied by severe symptoms such as fever and abdominal pain, while adults often have milder forms of the disease. With age, the immune response may weaken, which may also affect the clinical course and severity of symptoms. In elderly patients, it is important to consider the presence of comorbidities that may complicate treatment and monitoring of the condition.
Questions and Answers
- What are visceral migrant larvae?
This is a condition caused by the migration of the larvae of some parasitic helminths through the tissues of the human body, which can cause inflammatory reactions in various organs. - What are the main symptoms of the disease?
Symptoms may include fever, cough, abdominal pain, and allergic reactions such as rash and itching. - How is this disease diagnosed?
Diagnosis is based on clinical manifestations, laboratory tests and instrumental methods such as ultrasound and CT. - How are visceral migrant larvae treated?
Treatment involves anthelmintic drugs such as albendazole and mebendazole, and in some cases surgery may be necessary. - What are the risk factors for this disease?
Risk factors include contact with contaminated soil, lack of sanitary knowledge and the presence of pets infected with helminths.
